LCM
NKTR icon

Lynx1 Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Lynx1 Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-137,923
Closed -$1.93M – 19
2024
Q1 		$1.93M Buy
137,923
+9,310
+7% +$97.5K 0.5% 13
2023
Q4 		$1.09M Buy
128,613
+10,825
+9% +$82K 0.43% 14
2023
Q3 		$1.05M Buy
+117,788
New +$1.13M 0.7% 15

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lynx1 Capital Management's NKTR Position: Q2 2024 in Review

Lynx1 Capital Management sold out of Nektar Therapeutics (NKTR) in Q2 2024, closing a stake of 137,923 shares — an estimated $1.93M sold.

Lynx1 Capital Management first reported a position in NKTR in Q3 2023 and held it in 3 quarters. The position peaked at $1.93M in Q1 2024. 133 funds tracked by Wall St. Rank hold NKTR as of Q2 2024.

  • Lynx1 Capital Management reported no remaining Nektar Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Lynx1 Capital Management sold 137,923 Nektar Therapeutics shares in Q2 2024, an estimated $1.93M.
  • Lynx1 Capital Management first reported a position in Nektar Therapeutics in Q3 2023 and held it in 3 quarters.
  • Lynx1 Capital Management's Nektar Therapeutics position peaked at $1.93M in Q1 2024.
  • 133 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2024.

Based on Lynx1 Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.